Adverum Biotechnologies, Inc.
ADVM
$2.25
-$0.04-1.75%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -153.16M | -133.29M | -101.42M | -107.17M | -120.21M |
| Total Depreciation and Amortization | 3.34M | 3.65M | 3.85M | 4.47M | 5.05M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 32.93M | 34.99M | 22.64M | 29.53M | 34.43M |
| Change in Net Operating Assets | 4.90M | 2.19M | -10.62M | -15.16M | -11.01M |
| Cash from Operations | -111.99M | -92.46M | -85.54M | -88.33M | -91.74M |
| Capital Expenditure | -518.00K | -388.00K | -519.00K | -793.00K | -813.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 11.94M | -41.50M | -47.06M | -15.24M | 54.13M |
| Cash from Investing | 11.42M | -41.89M | -47.58M | -16.04M | 53.32M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 239.00K | 120.12M | 120.12M | 120.12M | 120.37M |
| Repurchase of Common Stock | -116.00K | -116.00K | -116.00K | -116.00K | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -76.00K | -182.00K | -420.00K |
| Cash from Financing | 123.00K | 120.00M | 119.93M | 119.83M | 119.95M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -100.45M | -14.35M | -13.19M | 15.46M | 81.53M |